Your session is about to expire
← Back to Search
Individuals with sickle cell trait for Sickle Cell Trait
N/A
Recruiting
Led By Julie Kanter, MD
Research Sponsored by National Alliance for Sickle Cell Centers
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 2 years
Awards & highlights
Study Summary
The main purpose of this study is to create a longitudinal cohort of those with Sickle Cell Trait (SCT) to better understand the hematologic phenotype for those that carry HbS, assess for differences in those with varying quantities of HbS and assess for potential clinical complications of SCT.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Hemoglobin variant quantification
Secondary outcome measures
Natural History
Red blood cell rheology
Trial Design
1Treatment groups
Experimental Treatment
Group I: Individuals with sickle cell traitExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
National Alliance for Sickle Cell CentersLead Sponsor
Beam Therapeutics Inc.Industry Sponsor
2 Previous Clinical Trials
117 Total Patients Enrolled
Julie Kanter, MDPrincipal InvestigatorNational Alliance for Sickle Cell Centers
2 Previous Clinical Trials
5,263 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger